The factors regulating growth of the developing lung are poorly understood, although the degree of fetal lung expansion is critical. The oncogene Trop2 (trophoblast antigen 2) is upregulated during accelerated fetal lung growth, and we hypothesized that it may regulate normal fetal lung growth. We investigated Trop2 expression in the fetal and neonatal sheep lung during accelerated and delayed lung growth induced by alterations in fetal lung expansion, as well as in response to glucocorticoids. Trop2 expression was measured using real-time PCR and localized spatially using in situ hybridization and immunofluorescence. During normal lung development, Trop2 expression was higher at 90 days gestational age (GA; 4.0 Ϯ 0.8) than at 128 days GA (1.0 Ϯ 0.1), decreased to 0.5 Ϯ 0.1 at 142 days GA (full term ϳ147 days GA), and was positively correlated to lung cell proliferation rates (r ϭ 0.953, P Ͻ 0.005). Trop2 expression was regulated by fetal lung expansion, but not by glucocorticoids. It was increased nearly threefold by 36 h of increased fetal lung expansion (P Ͻ 0.05) and was reduced to ϳ55% of control levels by reduced fetal lung expansion (P Ͻ 0.05). Trop2 expression was associated with lung cell proliferation during normal and altered lung growth, and the TROP2 protein colocalized with Ki-67-positive cells in the fetal lung. TROP2 was predominantly localized to fibroblasts and type II alveolar epithelial cells. Trop2 small interfering RNA decreased Trop2 expression by ϳ75% in cultured fetal rat lung fibroblasts and decreased their proliferation by ϳ50%. Cell viability was not affected. This study demonstrates that TROP2 regulates lung cell proliferation during development.
ADEQUATE GROWTH AND DEVELOPMENT of the lungs during fetal life are critical for survival after birth, when the lungs take over the role of gas exchange. Although the degree of lung expansion and exposure to glucocorticoids are critical regulators of fetal lung growth and development during late gestation (3, 26, 29, 45, 60) , the mechanisms underlying their effects remain largely unknown. Identifying these mechanisms may lead to improved therapeutic options for infants born with inadequately developed lungs due to preterm birth or lung hypoplasia.
The fetal lungs are filled with liquid, which is secreted by the lung and leaves via the trachea (24, 27) . During apnea, adduction of the fetal glottis retards the loss of liquid from the lungs, causing it to accumulate within the lung lumen and expand the lungs. If the degree of lung expansion is reduced, lung growth, structural development, and alveolarization cease (3, 45, 47) . Conversely, if the fetal trachea is obstructed [tracheal obstruction (TO)], the lungs overexpand with accumulated liquid, which accelerates lung growth and alveolarization, thins the alveolar walls, increases air space volume, and promotes differentiation of alveolar epithelial cells (AECs) (14, 18, 26, 43, 45, 48) .
The endogenous increase in fetal plasma glucocorticoid concentrations before birth is also critical for maturation of the fetal lung; it thins alveolar walls, stimulates alveolarization, increases air space volume, and stimulates surfactant synthesis (7, 8, 29, 60) . Thus, synthetic glucocorticoids are routinely administered to women at risk of preterm labor, although the doses used can lead to decreased lung growth and alveolarization in rats and rabbits (31, 44) . Although an increase in fetal lung expansion and glucocorticoids is critical for promoting fetal lung development, very little is known of their underlying mechanisms. However, both are likely to be mediated by alterations in the transcription of genes that regulate lung cell proliferation, differentiation, and extracellular matrix remodeling (6, 57) .
We recently identified Trop2 [also known as tumor-associated signal transducer 2 (Tacstd2)] as a gene upregulated by 36 h of increased lung expansion in fetal sheep (57) just prior to an ϳ800% increase in lung cell proliferation rates (28, 48) . The TROP2 protein is a cell surface glycoprotein receptor (21) that, when stimulated, increases intracellular calcium levels (53) . An increase in intracellular calcium is an important mediator of normal and stretch-induced lung growth (23, 39, 50) . Numerous studies have demonstrated that TROP2 promotes cell proliferation in tumor cells (13) and is involved in the formation, growth, and metastasis of tumors (19, 30, 37, 51, 55) . In the lung, Trop2 is expressed during fetal development (40, 57, 58) and is highly upregulated in adult lung tumors (30, 55) , when cell proliferation rates are high. As organogenesis and tumorigenesis are thought to share common regulatory pathways, we hypothesized that TROP2 may promote cell proliferation in the developing lung.
Our aims were 1) to compare Trop2 mRNA levels with lung cell proliferation during normal lung development and in models of altered lung development induced by alterations in lung expansion or glucocorticoid levels, 2) to investigate the colocalization of TROP2 with proliferating cells in the developing fetal lung, and 3) to investigate the effects of Trop2 knockdown on cell proliferation in cultured fetal lung cells.
METHODS
The Monash University Committee for Ethics in Animal Experimentation approved all experimental procedures involving the use of animals.
Ovine Experimental Groups
Lung tissues used in the study were previously collected from fetal sheep and newborn lambs during normal lung development (18) , accelerated fetal lung growth induced by TO, and decreased fetal lung growth induced by lung liquid drainage (7, 26, 47, 48) . Lung tissue was also collected from fetal sheep with decreased cortisol levels induced by fetal adrenalectomy (ADX) and increased glucocorticoid levels induced by fetal cortisol infusion or maternal betamethasone treatment (7, 12, 60) .
Normal lung development. Fetuses and lambs used to assess the ontogeny of Trop2 expression during normal lung development were not exposed to any experimental manipulation. Lung tissues were collected from fetal sheep during the canalicular stage of lung development at 90 (n ϭ 4), 105 (n ϭ 3), and 111 (n ϭ 4) days gestational age (GA) and during the saccular/alveolar stage of lung development at 125 (n ϭ 4), 128 (n ϭ 5), 138 (n ϭ 4), and 142 (n ϭ 5) days GA (full term ϳ147 days GA) and from lambs at 2 wk postnatal age (n ϭ 5) (17) .
Increased and decreased fetal lung growth induced by altered lung expansion. Lung growth was altered in chronically catheterized fetuses by manipulation of the degree of fetal lung expansion, as previously described (26, 47, 48) . Briefly, during aseptic surgery, two large-bore, saline-filled catheters were inserted into the fetal trachea: one was directed toward the fetal lung and the other toward, but not entering, the larynx. The tracheal catheters were exteriorized from the ewe and connected to form a continuous, exteriorized tracheal loop, which allowed the normal flow of liquid through the trachea prior to experimental intervention. At least 5 days were allowed for recovery from surgery before experiments commenced.
Increased lung expansion was induced by obstruction of the exteriorized tracheal loop (TO), which prevents the normal egress of liquid from the fetal lung, causing the lung to expand with accumulated liquid and, thereby, accelerating fetal lung growth. The obstruction was maintained for 36 h (n ϭ 5), 2 days (n ϭ 4), 4 days (n ϭ 5), and 10 days (n ϭ 5). We previously showed that TO increases cell proliferation rates by ϳ800% within 2 days; proliferation rates then rapidly decrease but remain higher than control levels for 7 days, at which time they are ϳ150% higher than controls (48) . The tracheal loop was not manipulated in control fetuses, thereby allowing the normal flow of liquid to and from the lung (0 day TO; n ϭ 5). All expansion and control periods ended at 128 days GA.
To decrease fetal lung growth, lung liquid was drained by gravity, via the tracheal catheter, for 7 (n ϭ 4) or 20 days (n ϭ 5), causing the degree of fetal lung expansion to be reduced (26) . At these time points, DNA content and DNA synthesis rates are substantially reduced (7, 26) , and lung growth essentially ceases over this time (47) . In age-matched control fetuses, the tracheal loop remained intact, allowing normal lung liquid flow through the trachea (n ϭ 4). All drainage and control periods ended at 131 days GA.
Reduced fetal plasma cortisol levels. In fetal sheep, circulating cortisol concentrations remain relatively low until ϳ2 wk before labor, when concentrations increase exponentially to Ͼ40 ng/ml (42, 60) . This increase in fetal cortisol matures many fetal organ systems, including the lung, and is responsible for labor onset in sheep (29) . Bilateral fetal ADX at 110 days GA (n ϭ 6) (60) was used to abolish this normal preparturient increase (135-147 days GA) in fetal cortisol concentrations. The controls (n ϭ 6) were sham-operated: their adrenal glands were exposed at surgery but not removed. Fetal plasma cortisol levels in control and ADX fetuses have been previously published (60) . Experimental and control periods ended at ϳ143 days GA.
Increased fetal cortisol levels. The prepartum increase in circulating fetal cortisol concentrations was mimicked by infusion of increasing doses of cortisol (hydrocortisone sodium succinate; Solu Cortef, Upjohn) into the jugular vein of fetal sheep (n ϭ 5) ϳ10 days before the normal onset of the preparturient cortisol increase. The infusion regimen involved administration of 1.5 mg/day on 122-123 days GA, 2.5 mg/day on 124 -125 days GA, 3.0 mg/day on 126 -127 days GA, 3.5 mg/day on 128 -129 days GA, and 4.0 mg/day on 130 -131 days GA; this regimen produces a significant increase in circulating cortisol concentrations comparable to the preparturient increase (7) . Control fetuses received continuous saline infusions for 9 days (122-131 days GA, n ϭ 5). Fetal plasma cortisol levels and lung cell proliferation rates in cortisol-and saline-infused fetuses are reported elsewhere (7, 59) . Experimental and control periods ended at 131 days GA.
Maternal betamethasone treatment. A bolus dose of betamethasone (11.4 mg im in 2 ml; Celestone Chronodose, Schering-Plough) was administered to pregnant ewes at 36 h and again at 24 h prior to euthanasia at 124 days GA (n ϭ 6) (12). The dose and timing are similar to dose and timing used clinically to mature the human fetal lung in women at risk of preterm delivery. Control ewes received a bolus injection of saline (2 ml im) at 36 and 24 h prior to euthanasia at 124 days GA (n ϭ 6) (12).
Tissue Collection
At the end of each experiment, liquid was drained from the fetal lungs, and all ewes, fetuses, and lambs were humanely killed by a lethal dose of thiopentone sodium (150 mg/kg iv) administered to the ewe or lamb. Fetal and lamb lungs were removed and weighed, the left bronchus was ligated, and the left lung was removed distal to the ligature. The right lung was fixed via the trachea using 4% paraformaldehyde in PBS (pH 7.4) with a constant distending pressure of 20 cmH 2O for later histological examination. Distal regions of the left lung were dissected into small (ϳ0.5-cm 3 ) pieces (with care taken to avoid major airways), frozen in liquid nitrogen, and stored at Ϫ70°C for later molecular analysis.
Lung tissues were also collected from fetal Sprague-Dawley rats. Dams were humanely killed by CO 2 inhalation at embryonic days 19 -20 (E19 -20 ; the day of plug was considered to be day 0 and full term is ϳE22) during the saccular stage of lung development. The fetuses (n ϭ 4) were humanely killed by decapitation, and the fetal lungs were used for the isolation of fetal lung fibroblasts or immersion-fixed in 4% paraformaldehyde for later histological examination. All fetuses (n ϭ 4) used for histology were from separate litters.
Isolation of Fetal Rat Lung Fibroblast Cells
Fetal rat lungs (E19) were washed in 1ϫ PBS (GIBCO) and chopped (0.8 mm 2 ) with a McIlwain tissue chopper (Lafayette Instruments). Chopped lung tissue was washed three times in 1ϫ PBS to remove blood cells and then vigorously pipetted in 25 ml of digestion buffer for Ͻ15 min to isolate cells from connective tissue. The digestion buffer contained 10% chicken serum (Sigma-Aldrich), 25 mM HEPES (GIBCO), collagenase types I and 1A (3.75 mg/ml; Sigma-Aldrich), and DNase I (0.38 mg/ml; Sigma-Aldrich) diluted in Waymouth's MB 752/1 medium (GIBCO, Invitrogen). Cells were then centrifuged for 5 min at 1,500 rpm, and the pellet was resuspended in Waymouth's MB 752/1 medium (10 ml/rat litter) containing 10% heat-inactivated fetal calf serum (GIBCO), 50 U/ml penicillin, and 50 g/ml streptomycin.
Fibroblasts were separated from epithelial cells by differential attachment. Briefly, the resuspended cell pellet was incubated in 75-cm 2 tissue culture flasks (5 ml of resuspended cells/flask) for 1 h at 37°C in 5% CO2; this is sufficient time for fibroblasts, but not epithelial cells, to attach to the flask. Attached fibroblasts were washed with 1ϫ PBS (2ϫ rinse, 1ϫ 5-min wash) and then trypsinized, centrifuged for 5 min at 1,500 rpm, and resuspended in Waymouth's MB 752/1 medium containing 10% heat-inactivated fetal calf serum, 50 U/ml penicillin, and 50 g/ml streptomycin. Cells were then counted using the Countess (Invitrogen) and seeded in tissue culture dishes at 1.3 ϫ 10 4 cells/cm 2 before incubation overnight at 37°C in 5% CO2.
siRNA Treatment of Cells
After overnight incubation, fetal lung fibroblasts were transfected with Trop2 small interfering RNA (siRNA; Stealth RNAi duplex 5=-CGACAGACCGAGCCUUCAACCACU-3=, Invitrogen) or a GCmatched control siRNA (33.3 nM; Stealth RNAi High GC negative control duplex, Invitrogen) using Lipofectamine RNAiMax transfection reagent (Invitrogen) diluted in Opti-MEM I reduced-serum medium (Invitrogen) and incubated for 6 h in Waymouth's MB 752/1 medium without antibiotics or fetal calf serum. After 24 h, medium was replaced with Waymouth's medium containing 10% heat-inactivated fetal calf serum, 50 U/ml penicillin, and 50 g/ml streptomycin. After 48 h, cells were collected for RNA or fixed for immunohistochemical analysis. Experiments were performed in triplicate and then repeated for each analysis.
Cell Viability
Trypsinized fibroblasts were collected, centrifuged, and resuspended in Waymouth's MB 752/1 medium containing 10% heatinactivated fetal calf serum, 50 U/ml penicillin, and 50 g/ml streptomycin. Cell suspensions were diluted 1:1 in Trypan blue (SigmaAldrich) and incubated for 5 min. The number of live cells (those that had not taken up the Trypan blue stain) were counted using a hemocytometer, and viability was calculated as percentage of total cells.
Real-Time PCR for Trop2 Gene Expression
Total RNA was isolated using the RNeasy mini RNA extraction kit (Qiagen). Briefly, samples were homogenized in lysis buffer, treated with DNase, precipitated with ethanol, and eluted in RNase-free water. Total RNA (1 g) was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen). Relative Trop2 mRNA levels were measured by real-time PCR using the housekeeping genes 18S rRNA for ovine samples and ribosomal protein 29 (Rps29) for rat samples; the primer sequences used to amplify these genes are listed in Table 1 .
PCR was performed using the Eppendorf Realplex Systems Lightcycler in 20-l reactions containing 1 l of cDNA (50 ng/l), 1 l of each primer (10 M), 10 l of SYBR green (Platinum SYBR Green quantitative PCR SuperMix-UDG, Invitrogen Life Technologies, Carlsbad, CA), and 7 l of nuclease-free water. PCR was carried out using an initial denaturation step at 95°C for 2 min, followed by 50 cycles of denaturation at 95°C for 3 s, annealing at 60°C for 20 s, and extension at 72°C for 20 s. A dissociation curve was performed after 50 cycles. The Trop2 mRNA level of each sample was analyzed using Realplex Systems analysis software. Each sample was measured in triplicate, and a negative control for each gene, containing no template, was included in every run. Trop2 mRNA levels in each sample were normalized to the 18S rRNA or Rps29 levels for that sample using the cycle threshold (⌬C t) method of analysis and expressed as a fold change relative to the mean Trop2 mRNA levels in the 128 days GA fetuses in the ontogeny study or to the respective control group for all other studies.
In Situ Hybridization for Trop2 in Fetal Sheep Lung Tissue
In situ hybridization was used to determine lung cell types expressing Trop2 in control fetuses (128 days GA) and in response to 36 h of TO (n ϭ 4 in both). Sense and antisense probes were generated by PCR using upstream 5=-GCCTGCTTGATTCTTGTCC-3= and downstream 5=-CCTATGCCAAACTGCCCTTA-3= primers to amplify a 204-bp region of Trop2 (GenBank accession no. DQ239625). In situ hybridization was performed on sections (5 m) from three different lobes of each fetus's lungs exactly as previously described (56), except the proteinase K solution was used at 5 g/ml and Trop2 sense and antisense probes (40 ng/l in hybridization solution) were used. A negative control section that omitted the anti-digoxigenin (DIG) antibody was included. Sections were examined at high power (ϫ100) using light microscopy and analyzed using ImagePro Plus (Media Cybernetics, Silver Spring, MD). The total number of cells and number of cells labeled with the antisense Trop2 probe were counted from at least three random fields of view per section; in total, Ն1,000 nuclei per fetus were counted. The number of nuclei positive for Trop2 was expressed as a percentage of the total number of cells counted for each fetus. The analysis was restricted to the alveolar region, with care taken to avoid major airways and blood vessels. Cells were classified as type II AECs (rounded cells bulging into the air space), type I AECs or endothelial cells (elongated cells with flattened nuclei adjacent to the luminal space), or fibroblasts (cells completely surrounded by tissue).
Immunohistochemistry for Ki-67
Paraffin-embedded ovine lung sections were stained with Ki-67 antibody (DakoCytomation) to quantify the percentage of cells undergoing proliferation, as described previously (17) . Rat fetal lung fibroblasts cultured on glass coverslips were fixed in 4% paraformaldehyde and then blocked with 10% BSA for 1 h. Cells were incubated with rabbit monoclonal anti-Ki-67 antibody (1:500 dilution; Thermo Scientific) overnight at 4°C and then with a goat anti-rabbit biotinylated IgG secondary antibody (1:200 dilution; Vector Laboratories) for 1 h. The secondary antibody was detected using a streptavidinbiotinylated horseradish peroxidase complex (1:200 dilution; GE Healthcare, Buckinghamshire, UK) and metal-enhanced diaminobenzidine (Thermo Scientific) according to the manufacturer's instructions, and the sections were counterstained with hematoxylin. Light microscopy was used to count the proportion of cells labeled with Ki-67.
The percentage of rat fibroblasts labeled with Ki-67 was calculated from triplicate coverslips with a total of 10 fields of view per triplicate. The total number of cells and the number of Ki-67-labeled cells were counted for each field of view from each coverslip, so that, 
Rps29, ribosomal protein 29. Digital images of ovine fetal lung tissue were captured and analyzed using ImagePro Plus. Three sections of lung tissue were analyzed per fetus: one each from the upper, middle, and lower lobes. The total number of nuclei and the number of Ki-67-positive nuclei per field of view were counted from at least five random fields of view per section, so that, in total, Ն1,800 nuclei per fetus were counted. The number of nuclei positive for Ki-67 was expressed as a percentage of the total number of cells counted for each fetus. The analysis was performed on the distal region of the lung, with care taken to avoid major airways and blood vessels.
TROP2 Colocalization With Ki-67, Surfactant Protein C, and ␣-Smooth Muscle Actin in Fetal Rat Lung Tissue
The TROP2 antibody did not cross-react with ovine TROP2; this limited TROP2 protein colocalization analyses to studies in fetal rat lung tissue. TROP2 antibody specificity was confirmed via Western blotting, with a single faint band detected at 40 kDa (data not shown). Serial sections (5 m) were labeled for TROP2, Ki-67, surfactant protein C (SPC), and ␣-smooth muscle actin (␣-SMA). Paraffinembedded lung sections were dewaxed and dehydrated. Appropriate antigen retrieval was performed for the protein of interest (Table 2) , and sections were incubated in serum-free protein block (DAKO) for 10 -30 min. Sections were incubated with the primary antibody overnight at 4°C and then with the secondary antibody (Invitrogen; Table 2 ). Sections were incubated in Sudan black [0.1% (wt/vol) in 70% ethanol; Sigma-Aldrich] for 5 min to eliminate background fluorescence and then mounted in antifade gold fluorescent mounting medium containing 4=,6-diamidino-2-phenylindole (Invitrogen).
Images from serial sections were acquired using a Nikon C1 confocal laser scanning microscope, aligned using Autoaligner (Bitplane), and analyzed with the analysis software ImageJ. One section through the whole lung was analyzed per fetus. For TROP2 and Ki-67 colocalization, the total number of nuclei, the number of nuclei positive for TROP2 or Ki-67, and the number of nuclei positive for both TROP2 and Ki-67 per field of view were counted from at least two random fields of view per section, so that, in total, Ն1,000 nuclei per fetus were counted. The number of nuclei positive for TROP2 or Ki-67 was expressed as a percentage of the total number of cells counted for each fetus. The number of nuclei positive for both TROP2 and Ki-67 was expressed as a percentage of the total number of cells positive for Ki-67. SPC and ␣-SMA were analyzed qualitatively for colocalization with TROP2.
Statistical Analysis
Values are means Ϯ SE. For all statistical tests, the data were tested for normal distribution before analysis, and P Ͻ 0.05 was considered significant. When only two groups were being compared, a nonpaired Student's t-test was used. When more than two groups were being compared, a one-way ANOVA was used. When significant differences were identified, a least significant difference post hoc test was performed to determine which groups were significantly different. The relationship between Trop2 mRNA levels and cell proliferation was tested by Pearson's product moment correlation. All statistical tests were performed using the software package SigmaStat. 
RESULTS

Trop2 mRNA Levels During Normal Lung Development in Sheep
Lung Trop2 mRNA levels were expressed as a fold change relative to the mean Trop2 mRNA levels measured at 128 days GA. Trop2 mRNA levels in the lung significantly decreased between 90 days GA and full term. They were highest and most variable at 90 days GA (3.97 Ϯ 0.78), were decreased by ϳ50% at 105 days GA (2.06 Ϯ 0.31), and were reduced further by 125 days GA (1.19 Ϯ 0.18, P Ͻ 0.05) compared with 105 days GA. Lung Trop2 mRNA levels remained similar between 125, 128 (1.00 Ϯ 0.12), and 138 days GA (1.01 Ϯ 0.2) but were decreased further
Relationship Between Trop2 mRNA Levels and Cell Proliferation During Normal Lung Development in Sheep
The percentage of proliferating cells in the lung markedly decreased during late gestation (17) in a pattern similar to Trop2 expression. Proliferation was highest at 90 days GA (8.66 Ϯ 1.70%), when Trop2 expression was highest, and was lowest at 142 days GA (1.72 Ϯ 0.30%), when Trop2 expression was lowest. There was a strong, positive, and significant correlation between Trop2 mRNA levels and the percentage of lung cells proliferating (r ϭ 0.953, P Ͻ 0.005; Fig. 1B) . The relationship is best described by the following equation: percentage of proliferating cells ϭ Trop2 mRNA level/0.45 ϩ 0.37.
Trop2 mRNA Levels During Altered Fetal Lung Growth in Sheep
Trop2 mRNA levels were significantly higher in the lungs of fetuses exposed to 36 h of TO (2.85 Ϯ 0.65, P Ͻ 0.05) than in control fetuses (1.00 Ϯ 0.19; Fig. 2A ) but were similar to control levels at 2 days (0.97 Ϯ 0.32), 4 days (0.75 Ϯ 0.11), and 10 days (0.59 Ϯ 0.13) of TO. In contrast, Trop2 mRNA levels were significantly lower in fetuses exposed to 7 days of lung deflation induced by lung liquid drainage (0.55 Ϯ 0.11) than in control fetuses (1.00 Ϯ 0.14, P Ͻ 0.05; Fig. 2B ). There was a small but nonsignificant decrease in Trop2 expression in the fetal lung following 20 days of lung liquid drainage (0.72 Ϯ 0.20) compared with control fetuses (1.00 Ϯ 0.19). 
Cell Proliferation Rates During Increased Lung Growth in Sheep
At 36 h of TO, the percentage of proliferating lung cells, determined by Ki-67 labeling, increased from 1.0 Ϯ 0.4% in controls to 5.2 Ϯ 0.7% (P Ͻ 0.05), representing an ϳ5.2-fold increase above control values (Fig. 3) . At 2 days of TO, the percentage of lung cells proliferating increased from 1.6 Ϯ 0.4% in controls to 7.3 Ϯ 2.3% (P Ͻ 0.05), which is an ϳ4.6-fold increase above control levels (Fig. 3) . Using [ 3 H]thymidine over an 8-h incorporation period, we previously showed an ϳ7.8-fold increase in cell proliferation rates at 2 days of TO (P Ͻ 0.05), which decreased to a 0.7-fold increase above control values by 4 days of TO (P Ͻ 0.05), and a return to control values by 10 days of TO (48) .
Localization of Trop2 mRNA in the Fetal Sheep Lung
In control fetuses, the lung cells expressing Trop2 were identified as predominantly fibroblasts and type II AECs (Fig. 4A) . A small number of elongated cells, likely to be endothelial cells or type I AECs, also expressed Trop2. In the proximal lung, Trop2 expression was observed in airway epithelial cells (Fig. 4D) and smooth muscle cells surrounding major blood vessels (Fig. 4E) . Trop2 mRNA localized to the same cell types in fetuses exposed to 36 h of TO and in control fetuses (Fig. 4 , B and C). Tissue incubated with the sense probe (Fig. 4F) or without the ␣-DIG antibody showed no labeling. The percentage of distal lung cells expressing Trop2 mRNA was significantly increased in fetuses exposed to 36 h of TO (21.02 Ϯ 3.00%) compared with controls (0.91 Ϯ 0.63%, P Ͻ 0.05; Fig.  4G ). It was also clear that the amount of Trop2 mRNA per cell was increased in fetuses that had undergone 36 h of TO. Fig. 2 . Effect of altered lung expansion on Trop2 mRNA levels in sheep lung tissue from control fetuses (n ϭ 5) and fetuses subjected to 36 h (n ϭ 5), 2 days (n ϭ 4), 4 days (n ϭ 5), and 10 days (n ϭ 5) of tracheal obstruction (TO; GA ϳ128 days in all fetuses; A) and control fetuses (n ϭ 4) and fetuses subjected to 7 days (n ϭ 4) or 20 days (n ϭ 5) of lung liquid drainage (B). Trop2 mRNA levels in all groups are expressed relative to levels of 18S rRNA transcript and as fold change relative to respective control group. Values are means Ϯ SE. *Significantly (P Ͻ 0.05) different from control. (n ϭ 4), 125 (n ϭ 4), 128 (n ϭ 5), 138 (n ϭ 4), and 142 (n ϭ 5) days gestational age (GA; full term ϳ147 days GA) and from lambs at 2 wk postnatal age (n ϭ 5). Trop2 mRNA levels are expressed relative to levels of 18S rRNA transcript in each sample and as fold change relative to 128 days GA group. Values are means Ϯ SE. Groups that share a common letter (e.g., "b" vs. "bc") are not significantly different from one another; groups that do not share a common letter (e.g., "a" vs. "bc") are significantly (P Ͻ 0.05) different from one another. B: relationship between percentage of proliferating cells (as determined by Ki-67 labeling index) and Trop2 mRNA level in fetal sheep at 90, 111, 128, 138, and 142 days GA and in lambs at 2 wk postnatal age. Values are means Ϯ SE. There is a significant (P Ͻ 0.005) correlation between the two factors (r ϭ 0.953). Relationship is best described by the following equation: y ϭ 0.454x Ϫ 0.369.
Localization of TROP2 Protein in the Fetal Rat Lung
The proportion of TROP2 protein-positive cells in the fetal rat lung (E20) was 56.8 Ϯ 3.5% of total lung cells. TROP2 was localized to the cell membrane and was present in the airway epithelium, endothelial cells, and parenchyma of the developing lung (Fig. 5A) . TROP2 was colocalized with cells expressing ␣-SMA (Fig. 5C ) and SPC (Fig. 5D ) in the conducting airways and the parenchyma (Fig. 5) .
In fetal rat lungs at E20, 44.5 Ϯ 2.9% of lung cells were positive for Ki-67. TROP2 was colocalized to cells expressing Ki-67 in the conducting airways and in the parenchyma (Fig. 5,  A and B) . Of the Ki-67-positive cells, 57.4 Ϯ 3.8% were also positive for TROP2, whereas 44.9 Ϯ 2.5% of TROP2-positive cells were also positive for Ki-67 (Fig. 6 ).
Trop2 mRNA Levels Following Altered Glucocorticoid Levels
Trop2 mRNA levels were significantly increased in fetuses that had undergone ADX (1.60 Ϯ 0.19, P Ͻ 0.05) compared with controls (1.00 Ϯ 0.12; Fig. 7 ). However, there was no change in Trop2 mRNA levels following a 9-day cortisol infusion (1.12 Ϯ 0.25) compared with saline-infused controls (1.00 Ϯ 0.15) or following maternal betamethasone treatment (1.26 Ϯ 0.24) compared with controls (1.00 Ϯ 0.09; Fig. 7 ).
Cell Proliferation Following Altered Glucocorticoid Levels
The percentage of lung cells proliferating was significantly higher following fetal ADX (1.69 Ϯ 0.39%) than in shamoperated control fetuses (0.64 Ϯ 0.22%, P Ͻ 0.05). The percentage of lung cells proliferating was similar in maternal betamethasone-treated fetuses (0.86 Ϯ 0.17%) and salinetreated controls (1.14 Ϯ 0.12%). We previously reported that fetal lung DNA synthesis rates are not altered by a 9-day cortisol infusion (59) .
Knockdown of Trop2 in Fetal Rat Lung Fibroblasts
With use of Lipofectamine RNAiMax, an 80.2% transfection efficiency was achieved in fetal rat lung fibroblasts when 
Cell Proliferation and Viability in Fetal Rat Lung Fibroblasts Following Knockdown of Trop2
The percentage of proliferating fibroblasts was significantly reduced following transfection with Trop2 siRNA (11.4 Ϯ 1.4%, P Ͻ 0.01; Fig. 8B ) compared with fibroblasts transfected with control siRNA (21.0 Ϯ 2.0%) or cells treated with transfection reagent only (16.3 Ϯ 2.1%). There was no difference in viability between cells transfected with control siRNA (97.6 Ϯ 1.4%), cells treated with transfection reagent only (98.5 Ϯ 1.2%), and cells transfected with siRNA specific for Trop2 (98.2 Ϯ 0.5%; Fig. 8C ).
DISCUSSION
This is the first study to examine Trop2 expression during normal fetal lung development and following alterations in fetal lung growth. Our results show a positive correlation between Trop2 mRNA levels and cell proliferation rates in the fetal and neonatal lung during the canalicular, saccular, and alveolar stages of lung development. We investigated Trop2 expression in the lungs of fetal sheep following alterations in lung growth induced by alterations in fetal lung expansion and glucocorticoid levels. In all cases, Trop2 expression was elevated in parallel with, or slightly preceding, an increase in cell proliferation, did not change when cell proliferation remained constant, and was reduced when cell proliferation rates were low. In addition, TROP2 protein was colocalized with proliferating cells in the fetal rat lung during normal development, with ϳ60% of proliferating cells coexpressing the TROP2 protein. Knockdown of Trop2 in fetal lung fibroblasts resulted in a 50% reduction in the proportion of cells proliferating. These studies support the contention that TROP2 plays an important role in regulating cell proliferation in the developing lung.
During accelerated fetal lung growth induced by an increase in lung expansion, Trop2 mRNA levels were highest (ϳ3-fold increase) at 36 h of TO, when there was an almost fivefold increase in cell proliferation. Thus, Trop2 expression peaks when the molecular events responsible for initiating the increase in cell proliferation are likely to be most active. In contrast, Trop2 mRNA levels were reduced by lung liquid drainage, which causes lung growth to cease (26, 47) . Thus, these data indicate that Trop2 expression is regulated by physiological factors (alterations in lung expansion) known to be critical regulators of fetal lung growth. The preparturient rise in fetal plasma cortisol is also a critical regulator of lung development, most notably by promoting an increase in fetal lung maturation (7, 8, 29, 32, 33, 60) . When the increase in cortisol was prevented by fetal ADX, Trop2 mRNA levels and lung cell proliferation were significantly elevated. There was no change in Trop2 expression with increased glucocorticoid levels induced by cortisol infusion or maternal betamethasone treatment. Consistent with our hypothesis, we found that lung cell proliferation rates were also not altered in those models. Unfortunately, we could not confirm TROP2 protein levels in any of the sheep models, as none of the available antibodies cross-reacted with the sheep TROP2 protein.
Measured using in situ hybridization, the percentage of distal lung cells expressing Trop2 mRNA was increased in fetuses exposed to 36 h of TO, confirming the increase measured by real-time PCR. On the basis of cell shape and location within the parenchyma, Trop2 was mainly expressed in type II AECs and interstitial fibroblasts but was also present in smooth muscle cells and airway epithelial cells. This observation is confirmed by our data in fetal rats, which demonstrates cell membrane localization of TROP2 protein in cells expressing SPC, which is a marker of type II AECs, and ␣-SMA, which is specific for smooth muscle cells and myofibroblasts within the distal lung parenchyma. Trop2 is expressed in cultured endothelial cells (22) and in the epithelial cells of a variety of organs, including the embryonic lung (40) and adult lung tumors (1, 25, 54, 55) . However, this is the first study to show that smooth muscle cells and myofibroblasts also express TROP2. Trop2 mRNA was also expressed in a small number of elongated cells within the distal lung. Although some of these cells could have been type I AECs, we believe they are more likely to be endothelial cells, because TROP2 protein was abundant in endothelial cells of large blood vessels in the fetal rat lung. The cell types that contain TROP2 (fibroblasts, type II AECs, and endothelial cells) are also the same cell types that proliferate in response to increased fetal lung expansion (49) . To examine this relationship more closely, we determined if TROP2 was colocalized with Ki-67, a marker of cell prolifer- ation. In the fetal rat lung, we found that ϳ60% of Ki-67-positive cells were also positive for TROP2, indicating that TROP2 is closely associated with cell proliferation in the developing lung.
Using Trop2 siRNA in primary cultures of distal fetal lung fibroblasts, we induced a 75% reduction in Trop2 expression, which led to a 50% decrease in the percentage of proliferating fibroblasts. The reduction in cell proliferation was not due to a loss of cell viability. These data provide clear evidence that Trop2 regulates the proliferation of fetal lung fibroblasts and suggest that it may have a major role in regulating fetal lung growth. It has previously been shown that ectopic overexpression of Trop2 in NIH 3T3 fibroblast cells increases cell proliferation and causes these cells to become highly tumorigenic when injected into mice (61) . However, this is the first study to demonstrate that Trop2 regulates normal proliferation of fibroblast cells and that Trop2 has a functional role in normal fetal, noncancerous cells.
Trop2 is a known oncogene (61) that promotes proliferation in cancerous cells in vitro (13) and tumorigenesis in vivo (61) . Trop2 expression is 20-fold higher in human lung carcinomas than in normal lung tissue (55) , is a prognostic marker for lung adenocarcinoma (30) , and is expressed in Ͼ70% of non-small cell lung carcinoma cell lines (11) . Trop2 is also highly upregulated in human colorectal, pancreatic, esophageal, oral, breast, and ovarian cancers (5, 16, 19, 20, 46, 51, 52, 61) and has been linked to increased metastasis and decreased survival (19, 51) . Importantly, the inhibition of Trop2 reduces tumorigenesis and invasiveness of cancer cells, while its overexpression promotes tumor formation (2, 25, 61) . These data provide compelling evidence that TROP2 plays an integral role in tumor cell proliferation and, when combined with our findings, indicates that TROP2 may assist in the control of normal cell proliferation in the developing lung.
The underlying mechanisms that regulate expansion-induced cell proliferation in the fetal lung are unknown; however, in vitro studies have shown that increased intracellular calcium and PKC are involved. Inhibition of mechanosensitive calcium channels prevents stretch-induced proliferation in cultured lung cells (39) , while stretch of type II AECs in culture activates PKC and promotes cell proliferation (38) . Although the mechanism by which TROP2 may regulate cell proliferation is not fully understood, it is also likely to involve PKC and an increase in intracellular calcium. Activation of TROP2 causes a transient increase in intracellular calcium (53) , which may be mediated by the calcium signaling molecules PKC and phosphatidylinositol 4,5-bisphosphate (10, 41) via the PKC phosphorylation site (15) and phosphatidylinositol 4,5-bisphosphate binding site in the cytoplasmic tail of TROP2 (4). A preliminary report has shown that deletion of the cytoplasmic region of TROP2, mutation of the PKC phosphorylation site, or expression of dominant-negative PKC abolish TROP2-induced tumor growth (2) . As these studies demonstrate, TROP2 regulates cell proliferation in tumor cells via the same pathways that have been implicated in expansion-induced fetal lung cell proliferation.
Although the majority of Ki-67-positive cells were also positive for TROP2, ϳ55% of TROP2-positive cells were not positive for Ki-67. It is possible that some of these cells were about to enter the cell cycle and, therefore, were not yet positive for Ki-67. It is also possible that TROP2 persists in the cell much longer than Ki-67, particularly as it is localized to the cell membrane; therefore, some of these cells may have already undergone cell division. Alternatively, TROP2 may have other roles. For example, TROP2 may promote lung cell migration, because it promotes the migration of a variety of cells in vitro (13) and metastasis in vivo (19, 51) . As migration of myofibroblasts is required for secondary septal crest formation during alveolarization (9, 35) , a potential relationship between TROP2 expression and cell migration in the fetal lung warrants further investigation.
Our finding that Trop2 is regulated by increased lung expansion indicates that mechanical forces regulate its expression. The Trop2 promoter contains a putative Sp1 binding site (36) , which has been identified as a sheer-stress response element in another membrane-bound glycoprotein, tissue factor (34) . To determine if glucocorticoids also regulate Trop2 expression, we measured Trop2 mRNA levels in ADX fetuses and fetuses exposed to elevated glucocorticoid levels. Although ADX increased (by ϳ60%) Trop2 mRNA levels late in gestation, neither a cortisol infusion nor maternal betamethasone treatment affected Trop2 expression. Thus the increase in Trop2 expression following ADX and the rapid reduction in Trop2 mRNA levels just prior to birth could be due to another adrenal-derived hormone or a cofactor that is not present in the lung until late in gestation. Further studies are required to determine the factors that regulate Trop2 expression in the lung, particularly between midgestation and birth.
In summary, we have shown that Trop2 expression in the lung decreases throughout the latter half of gestation and is positively correlated to cell proliferation during normal lung development. Trop2 expression is also positively associated with changes in lung cell proliferation following alterations in fetal lung expansion or glucocorticoid levels. In the fetal lung, TROP2 is primarily localized to fibroblasts and type II AECs. TROP2 is present in cells that are actively proliferating in vivo, and knockdown of Trop2 resulted in a decrease in the proliferation of primary fetal lung fibroblasts in vitro. We have also identified mechanical strain as a potent regulator of Trop2 expression. Thus our data indicate that Trop2 is likely to play an important role in expansion-induced fetal lung growth and development through regulation of fetal lung cell proliferation. The mechanisms that underlie TROP2 regulation of lung cell proliferation warrant further investigation.
